Mylan Pharmaceuticals` Zonisamide Mylan (Zonisamide) Receives Approval in Europe
Amdipharm`s Zonegran Receives Approval in Europe
DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked...
Enforcement Report - Week of May 4, 2022
Enforcement Report - Week of September 29, 2021
Eisai announced that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma.
Unichem Labs Generic Zonisamide Receives Approval in US
DEER PARK, Ill., July 30, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has submitted a new drug application (NDA) for zonisamide oral suspension, previously known as the company’s ET-104 product candidate, to the U.S. Food & Drug Administration (FDA) for the treatment of partial seizures in patients with epilepsy.
Mylan S.A.S.`s Zonisamide receives marketing authorisation in EU for Epilepsy